Buserol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buserol

Buserol is a prescription-only medicine that acts as a highly specialized hormonal agent used to achieve therapeutic suppression of sex hormone levels in the body. Its core function is to modulate the body's natural hormonal communication pathways by regulating the pituitary-gonadal axis.


Quick Facts

Property Description
Active ingredient Buserelin acetate
Form Solution for injection (including depot), nasal spray
Pharmacological class Gonadotropin-releasing hormone (GnRH) analogue (agonist)
General purpose To induce sustained hormonal downregulation
Origin Synthetic peptide (nonapeptide)

Buserol: Classification and Identity as a GnRH Analogue

Buserol's identity is defined by its active pharmaceutical ingredient, Buserelin acetate, a synthetic peptide that structurally mimics the natural Luteinizing Hormone-releasing Hormone (LHRH). Buserelin is specifically classified as a GnRH agonist, a class that is clinically recognized for its therapeutic efficacy in achieving a specific hormonal profile. The function of this GnRH analogue is to act directly on the pituitary gland, the key regulator of the hormonal system.

This regulatory mechanism is considered a foundational principle of hormonal control therapy. The classification means this medicine is used when a consistent, deep reduction in the body's natural sex hormone production is required for a therapeutic effect, such as managing hormone-sensitive conditions.

Composition and General Purpose: Hormonal Downregulation

The Buserelin molecule is a highly specific, laboratory-derived synthetic nonapeptide. This molecular design enables it to act as a potent Pituitary-gonadal axis regulator. Buserelin is notably one of the few GnRH analogues available in an intranasal spray formulation, offering an alternative to standard subcutaneous or intramuscular aqueous solution for injection. The injectable forms include a depot preparation that utilizes a specialized polymer matrix for the sustained, slow release of the active ingredient.

The overall purpose of Buserol is to induce sustained hormonal downregulation. This action, achieved through persistent signaling, forces the body to decrease the production of key sex hormones, specifically testosterone and estradiol. This controlled, therapeutic reduction of circulating sex hormones is the fundamental functional benefit provided by Buserol.

What side effects are possible with Buserol?

Possible side effects and safety information

The safety profile of Buserol (buserelin acetate), a Gonadotropin-releasing hormone (GnRH) analogue, reflects its intended function of inducing sustained suppression of sex hormone levels, which often leads to expected, hormone-related adverse reactions, as documented in regulatory sources.

Frequency-Classified Adverse Reactions

Side effects are categorized by frequency, consistent with official regulatory classification systems:

  • Very Common (Affecting 1 in 10 patients): Hot flushes/hot flashes, headache, and transient local reactions at the injection site.
  • Common (Affecting 1 in 100 patients): Dizziness, sleep disturbances, nausea, vomiting, sweating, mood changes, and effects consistent with hormone deprivation, such as reduced libido, impotence, and vaginal dryness.
  • Uncommon/Rare/Very Rare: Less frequent reactions include anxiety, palpitations, rash, pruritus, and, in rare instances, severe hypersensitivity reactions such as anaphylactic shock and angioedema.

Documented Safety Patterns and Serious Risks

Official labeling describes safety risks related to the timing and duration of use:

  • Initial Hormonal Flare: At the start of treatment, a transient surge in sex hormones occurs before suppression takes effect. This can lead to a temporary worsening of pre-existing symptoms, which may include bone pain or urinary difficulties.
  • Long-Term Exposure: Prolonged treatment is associated with a risk of decreased bone mineral density.

Serious adverse reactions, though rare, are officially documented, including pituitary apoplexy in patients with known pituitary adenoma, and severe allergic reactions. Safety constraints note that the medicine is contraindicated in cases of hypersensitivity to GnRH analogues, undiagnosed vaginal bleeding, pregnancy, and lactation.

Population-Specific Safety Considerations

The label includes safety notes for particular patient groups. For instance, the potential for altered glucose tolerance necessitates monitoring in diabetic patients, and caution is warranted for individuals with a risk of cardiovascular or metabolic disease.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Buserol primarily involving gastrointestinal and central nervous system effects. Documented presentations of overdose include nausea, vomiting, dizziness, drowsiness, miosis (unusual constriction of the pupils), and general gastric distress. Clinical trial data indicated that symptoms of overdose were documented at a daily dose of 375 mg.

Overdoses with Buserol have generally resulted in complete recovery; however, severe outcomes, including a fatality, have been reported in cases where Buserol was taken in co-ingestion with other substances, such as alcohol and central nervous system depressants. This underscores the need for immediate, professional medical attention.

Required Emergency Actions

If an overdose of Buserol is suspected or known, emergency medical help must be sought at once, regardless of whether or not symptoms are currently present. Contact the Poison Help line or proceed to an emergency department immediately.

Emergency treatment focuses on general symptomatic and supportive measures, as there is no specific antidote known for Buserol. Required supportive actions include immediate gastric lavage (stomach emptying) and continuous monitoring of vital signs, including respiration, pulse, and blood pressure. The drug's dialyzability has not been determined in the official documentation.

Therapeutic Uses of Buserol

The use of Buserol (buserelin acetate) involves sustained hormonal downregulation, a central therapeutic focus that generally helps manage specific clinical conditions and the challenging symptoms they generate. Its use is concentrated in therapeutic areas where suppressing the effects of key sex hormones is necessary to control disease progression or ease symptom burden.


Therapeutic Scope and Relief

Buserol is commonly used in addressing indications such as advanced prostate carcinoma, specific types of premenopausal breast cancer, benign conditions like endometriosis and uterine fibroids (leiomyoma), and Central Precocious Puberty (CPP). It contributes to easing the overall symptom load by addressing conditions linked to hormone-driven progression and may assist with establishing regulation for Assisted Reproductive Technology (ART) protocols.

“The therapeutic approach involves managing conditions where symptom fluctuations are driven by hormonal activity, which helps patients cope more steadily with those changes.”


Quick Fact: Relief for Symptom Categories

Therapeutic Domain Primary Symptom Benefit
Oncology Supportive palliative relief and management of disease progression.
Gynecology Easing severe chronic pain and reducing the size of lesions.
Pediatrics Managing the rate of premature physical development.
Reproduction Assisting with managing the timing of cycles for procedures.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Buserol

The eligibility for Buserol (buserelin acetate) is strictly defined by government regulatory documents based on patient population, hormonal status, and pre-existing conditions.

Populations for Whom Use is Allowed

Buserol is approved for use in men with hormone-dependent advanced prostate carcinoma, women for specific hormone-sensitive gynecological conditions (e.g., endometriosis, uterine fibroids), and pediatric patients for Central Precocious Puberty (CPP).

Populations for Whom Use is Contraindicated

Buserol is absolutely contraindicated in several patient groups, including pregnant or breastfeeding women, women with undiagnosed abnormal vaginal bleeding, and patients with documented hypersensitivity to the drug or GnRH. Use is also prohibited in men who have undergone bilateral orchiectomy or whose prostate cancer is not hormone-dependent. The injectable formulation is contraindicated in newborns and premature neonates due to excipient safety concerns.

Eligibility-Related Restrictions

Use is restricted or requires special caution in patients with severe hepatic or renal impairment, as well as those with pre-existing diabetes mellitus, hypertension, pre-existing depression, or significant risk factors for osteoporosis. Women of childbearing potential are required to use effective non-hormonal contraception during therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Buserol (buserelin acetate) based on pharmacodynamic effects, exposure modification, and administration requirements. The medicine is a synthetic peptide, and its labels do not list clinically significant interactions mediated by Cytochrome P450 enzymes.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Official Interaction Pattern
Antidiabetic Agents Co-administration may result in the attenuation (reduction) of their therapeutic effect, impacting glucose control.
QTc-Prolonging Medicines Concomitant use increases the risk of QTc prolongation or Torsade de pointes, as Buserol itself is associated with this effect.
Grapefruit juice Consumption may increase the circulating levels of buserelin in the body.

Administration and Population-Related Constraints

When Buserol is administered as a nasal spray, regulatory documents specify a mandatory time separation must be observed before using any other nasal spray (e.g., decongestants) to ensure proper absorption. For the injection solution, the excipient benzyl alcohol carries a documented risk of accumulation and associated side effects in patients with pre-existing severe liver or kidney disease.

Mechanism of Action

How Buserol Works

Buserol, a synthetic peptide, executes its physiological action through a sequential, biphasic modulation of the central Hypothalamic-Pituitary-Gonadal (HPG) axis.


Central Pituitary Receptor Targeting and Shutdown

The drug's mechanism begins centrally by acting as a GnRH agonist for the Gonadotropin-releasing Hormone Receptors ( GnRH-R) on the pituitary gland. Initial, intense, and prolonged binding causes a short-term surge (the "flare") in downstream hormones. This continuous, non-pulsatile stimulation leads the receptors into a state of desensitization and subsequent downregulation. This functional shutdown of the GnRH-R neutralizes the pituitary's ability to receive and transmit central hormonal commands.


Sustained Suppression of Steroid Synthesis

The resulting receptor desensitization terminates the release of the necessary signaling hormones, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This cessation of LH/FSH release leads to a systemic suppression of gonadal steroidogenesis. The physiological consequence of this mechanism is a sustained reduction of circulating Testosterone and Estradiol concentrations to levels characteristic of a hypogonadal state.

Dosage and Administration Information

The administration of Buserol (buserelin acetate) is determined by its specific route and dosing schedule. The medicine is utilized via a subcutaneous (SC) injection (solution) or an intranasal (IN) spray (solution).

Administration patterns vary. For gynecological conditions and pituitary down-regulation in Assisted Reproductive Technology (ART) protocols, the SC injection is commonly administered once daily at doses typically ranging from 200 µg to 500 µg. In contrast, maintenance regimens for certain advanced conditions often involve the nasal spray, which requires multiple divided doses daily to achieve a total dose between 900 µg and 1200 µg. Initial administration is often supervised by a healthcare professional, with training provided for subsequent self-injection.

A crucial aspect of the usage protocol is the treatment duration constraint for benign conditions; for example, the total course for uterine fibroids or endometriosis is typically limited to a maximum of six to nine months. Procedural instructions also state that the solution must be visually inspected before use and that a missed dose should not be compensated by taking a double dose. This structure ensures adherence to the established high-level use pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Buserol

Buserol was evaluated in studies for various conditions that involve hormonal activity. The research primarily relies on controlled trials and long-term follow-up studies. Understanding this evidence involves looking at what was studied for these conditions and where researchers still see unanswered questions.


Evidence for Use in Hormone-Sensitive Prostate Carcinoma

Research related to Buserol was evaluated in studies involving adult males diagnosed with advanced prostate cancer. The core functional measures tracked were studied, including the progression of the disease and the overall patient observation time. Biomarker shifts, specifically in the prostate-specific antigen (PSA) level, were monitored as a way to track the cancer’s status.

The data show patterns related to the suppression of testosterone and describe the frequency of measured levels falling into the range considered castrate levels. Evidence is limited for Buserol's use in the most modern combination regimens, and the results apply only to the populations studied.


Evidence for Use in Gynecological Conditions (Endometriosis and Uterine Fibroids)

Buserol was studied for gynecological conditions, including endometriosis, which is a condition characterized by fluctuating or episodic manifestations. Studies examined patient-reported outcomes describing perceived discomfort, such as measures for pelvic pain and menstrual pain. Objective measures were monitored, including the regression or size reduction of endometriotic lesions documented by physical examination or imaging.

Long-term effects are not fully established for this indication. Follow-up durations were limited in many key trials, meaning that data for symptom recurrence rates or the durability of the response years after treatment cessation are not well characterized.


Evidence for Use in Central Precocious Puberty (CPP)

Buserol was studied for children and adolescents diagnosed with Central Precocious Puberty (CPP). Studies examined outcomes related to systemic or functional imbalance by tracking hormonal suppression and monitored physical changes using measurements like Tanner staging for secondary sex characteristics. A major focus of the research was observed in outcomes reflecting growth, such as the rate of bone age maturation velocity and the projected Predicted Final Adult Height (PAH).


What is Still Uncertain About Buserol's Clinical Research

Across all indications, evidence quality varies across studies, and many of the original results apply only to the populations studied in the initial, controlled trials. Data for certain groups remain insufficient. It is known that research is ongoing to fully understand the long-term patterns and the optimal positioning of Buserol alongside the newest competing therapies for all of its studied indications.

Frequently Asked Questions (FAQ)

Common questions about Buserol (FAQ)


Q: Is Buserol a steroid?

A: No, Buserol is not chemically categorized as a steroid. Official drug classification identifies it as a synthetic peptide that belongs to the Gonadotropin-releasing Hormone (GnRH) analogue class. Its function is to regulate the body's hormonal system to suppress the production of sex hormones (steroids), but it is a different chemical type.


Q: Is Buserol a controlled substance?

A: Regulatory drug schedules classify medicines based on their potential for misuse. According to official drug classification information, the active ingredient in Buserol, buserelin acetate, is not listed as a controlled substance under major international regulatory schedules.


Q: How long does it typically take to notice the effects of Buserol?

A: Official information describes Buserol's action as biphasic, meaning it has two phases. First, an initial, transient hormonal surge (known as a 'flare') occurs, followed by the main therapeutic goal: sustained hormonal suppression. The time required to achieve the full, sustained therapeutic effect and for effects to be observed can vary between individuals and formulations.


Q: Why do some people say Buserol made them feel tired?

A: While tiredness or fatigue may not be listed explicitly as a side effect, regulatory documents describe several related common adverse effects. These include sleep disturbances, mood changes, and general effects consistent with hormone deprivation, which may be reported as fatigue.


Q: Is it normal to feel a change in appetite with Buserol?

A: The official product information lists common hormone-related adverse effects such as nausea and vomiting. However, a specific change in appetite is not generally listed among the most frequent adverse reactions documented in the regulatory adverse event summaries.


Q: Are there specific food types that are noted to interact with Buserol?

A: The official documentation on interactions specifically mentions one food type. Consumption of grapefruit juice may lead to an increase in the circulating levels of the active ingredient in the body. Official information describes this interaction.


Q: How long after stopping Buserol do the effects wear off?

A: The hormonal suppression caused by Buserol is generally considered reversible once treatment has ended. The time required for the body’s natural hormonal functions to resume can vary depending on individual health factors, the duration of use, and the approved indication it was used for.


Q: What kind of studies have been done on Buserol?

A: The evidence supporting Buserol's approved uses comes primarily from controlled clinical trials and long-term follow-up studies. These investigations focused on tracking metrics like hormone levels, specific biomarkers (such as PSA), and physical development or disease manifestation, depending on the condition being studied.


Q: Is Buserol prescribed for anything besides the main approved use?

A: Official regulatory documents define the specific, approved indications for which Buserol can be prescribed, such as advanced prostate cancer and certain gynecological conditions. The label does not provide information for uses that fall outside of these officially approved indications.


Q: Can Buserol affect the results of lab tests?

A: The medicine functions as a hormonal regulator, and its effect on laboratory values is expected. Because it achieves its therapeutic effect by suppressing the body's natural sex hormones, it will affect blood levels of hormones such as Testosterone, Estradiol, LH, and FSH.


Q: Are there any long-term effects of taking Buserol that people talk about?

A: Official documentation notes that prolonged treatment with Buserol is associated with a risk of decreased bone mineral density (bone thinning). Additionally, follow-up research is often noted to be limited, meaning the data on the long-term durability of the response is not fully characterized for certain uses.


Q: Is Buserol safe to take with common vitamins?

A: Regulatory documents list interactions with certain drug classes and substances. However, official product labeling does not typically include specific warnings or general advice regarding common vitamins or standard dietary supplements.


Q: Is Buserol available in a generic version?

A: The active ingredient in Buserol is buserelin acetate. This active pharmaceutical ingredient is widely referenced in manufacturing records and is available as a component in various pharmaceutical products, including both branded and generic preparations.


Q: Are there any warnings about Buserol and driving or operating machinery?

A: Official patient information advises caution when driving or operating machinery if a patient experiences certain side effects. These specifically include effects such as dizziness or vision disturbances.


Q: Is Buserol used in combination with other medicines often?

A: Official clinical protocols and trial data indicate that Buserol may be used as part of combination therapy for its approved uses. For example, it is sometimes used as an adjunct (an add-on) to other hormone-based treatments or in assisted reproduction protocols.


Q: Are there different strengths of Buserol available?

A: Yes, Buserol is officially available in different presentations, including a solution for injection and a nasal spray formulation. These various forms and presentations are associated with different concentrations and different total daily dose ranges, as described in official prescribing information.


Q: Can Buserol be used by teenagers?

A: Official regulatory documents confirm that Buserol is approved for use in pediatric patients, which includes adolescents. Specifically, it is indicated for the treatment of children and teenagers diagnosed with Central Precocious Puberty (CPP).


Q: Does Buserol affect fertility?

A: The drug is a potent hormonal agent whose mechanism of action is to induce suppression of the sex hormone system, which directly impacts reproductive function. Official documents classify the active ingredient as a fertility agent in some contexts and lists pregnancy as a contraindication.


Q: What is the difference between Buserol and a placebo in clinical trials?

A: In clinical trials, Buserol is compared against a placebo, which is an inactive substance. Buserol is an active hormonal analogue designed to suppress sex hormone levels, while the placebo has no biological effect. This comparison allows researchers to measure the drug’s observed effect on patient outcomes, such as measured hormone levels.


Q: Does Buserol make you sensitive to the sun?

A: Photosensitivity, or an increased sensitivity to the sun, is not officially listed as one of the commonly or very commonly reported side effects. The official regulatory summary of adverse reactions does not include a specific warning about sun sensitivity.


Q: Are the effects of Buserol permanent after stopping treatment?

A: The hormonal suppression achieved by the medicine is generally described in official sources as being reversible upon discontinuing the treatment. The body’s hormonal functions are generally anticipated to return after cessation. Follow-up research notes that data on the long-term durability of the response is limited for certain uses.


Q: How reliable is the evidence that Buserol works for its approved use?

A: Buserol is approved by government bodies after assessing the evidence from clinical trials. Official research summaries report that evidence quality varies across studies and is often limited to the populations studied in the initial, controlled trials. Data for certain groups may be insufficient.

How should Buserol be stored and disposed of?

How to Store and Dispose of Buserol (Buserelin Acetate)

The official storage and disposal requirements for Buserol are defined by regulatory documents to maintain the product's stability and ensure safety.

Mandatory Storage Conditions

Storage Category Requirement
Temperature Do not store the injection solution above 25 C and do not freeze.
Protection Vials must be kept in the outer carton to protect the contents from light, heat, and moisture.
Child Safety The medicine must be stored out of the reach of children.

Stability and Disposal Rules

For multi-dose injection vials, stability is limited after initial opening, and the contents must be used within 15 days.

Any unused or expired product must be handled as pharmaceutical waste. Disposal must be performed in accordance with local requirements to avoid releasing the substance to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buserol found in:

A-Z Index: